Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Multicenter, Open-label Phase I/II Investigational Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KY-0301 as Monotherapy in Patients With Advanced Solid Tumors.

NCT06928363 is registered in ClinicalTrials.gov with Novatim Immune Therapeutics (Zhejiang) Co., Ltd. as lead sponsor.

NCT NCT06928363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06928363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Multicenter, Open-label Phase I/II Investigational Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of KY-0301 as Monotherapy in Patients With Advanced Solid Tumors.
Lead sponsor
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 1, 2025
Completion date
December 15, 2027
Enrollment
212 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors